What Is BPC-157?

BPC-157 is a synthetic pentadecapeptide — a chain of 15 amino acids — designed to reproduce part of a protein that researchers identified in human gastric juice. It is not an approved drug, it has essentially no completed human clinical trial record, and it is named on the World Anti-Doping Agency's list of substances banned in sport.

What BPC-157 actually is

The name stands for "body protection compound," and the number refers to its place in a numbered series of candidate sequences researchers worked through decades ago. The molecule itself is small: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a chain with a molecular weight of about 1,419.55 daltons, according to a 2025 literature and patent review published in the journal Pharmaceuticals. That is roughly a hundredth the size of a typical antibody, and far smaller than a protein like insulin.

Researchers describe BPC-157 as a fragment of a larger parent protein found in gastric juice, not an extract taken directly from it — the working sequence was synthesized in a lab to match a portion of that larger molecule. The same review notes BPC-157's stability in gastric juice and water is unusual for a peptide of its size, which is part of what drew research attention to it in the first place: most short peptides break down quickly in an acidic environment, and this one doesn't.

Where the name and the research program came from

The compound traces to a research group led by Predrag Sikiric at the University of Zagreb, which first described it in a 1993 paper. A US patent application covering the parent protein followed in 1994. Sikiric's group has published the large majority of the animal literature on BPC-157 since then — more than 150 papers, by the Pharmaceuticals review's count — making the compound's research record unusually concentrated in one lab's output rather than independently replicated across many groups.

What has actually been studied, and in what models

The animal literature is genuinely large. Rats, mice and, for some pharmacokinetic and toxicity work, beagle dogs have been used to examine BPC-157 in models of gastrointestinal injury, tendon and ligament damage, skin wounds, and nerve injury, among others. The 2025 Pharmaceuticals review also catalogs animal studies touching on wound healing broadly, cancer cachexia, pain, alcohol-related tissue injury, and neuropsychiatric endpoints — a wide spread of research questions, all addressed in rodent or canine models rather than in people. Researchers studying these models describe effects on angiogenesis — the growth of new blood vessels into damaged tissue — and nitric-oxide signaling as proposed mechanisms behind what they observe, though the review notes most of this work has been limited to a small number of labs and administration routes.

Human data are a different story. The 2025 Pharmaceuticals review found a retrospective study of 12 patients who received intra-articular injections for knee pain, which the authors themselves describe as "not overly informative and reliable" because no validated measurement tool was used to track outcomes. A Phase I safety trial in 42 healthy volunteers was registered on ClinicalTrials.gov in 2015 (NCT02637284); according to the review, the researchers cancelled submission of the trial's results in 2016, so no outcome was ever published. The review's own conclusion is direct: "there are no completed clinical studies describing its efficacy in humans."

That gap matters for a specific reason beyond the usual animal-to-human uncertainty. BPC-157's proposed mechanism — promoting new blood vessel growth into damaged tissue — is the same general process implicated in tumor growth. Researchers who study the compound have flagged this as a theoretical concern worth studying, not a demonstrated risk; nothing in the published animal literature shows BPC-157 causes cancer. But it's a question that a controlled human trial, not an animal study, would be positioned to answer, and that trial hasn't happened.

Regulatory status in the United States

BPC-157 is not an FDA-approved drug for any use. Its history with the agency's compounding rules has been unusually active. The FDA's own page on bulk drug substances that may present significant safety risks in compounding lists BPC-157 not in Category 2 (its active safety-risk list) but in a separate table for substances whose nominations were withdrawn by the nominators who originally proposed restricting them — a status distinct from being cleared. The same page flags a potential risk the agency associates with compounded BPC-157: immunogenicity concerns for certain routes of administration, alongside a general lack of safety information. Removal from that withdrawn-nomination status doesn't put a substance on the list of bulk substances pharmacies may legally compound with; that's a separate FDA determination the agency has been actively reviewing.

Status in competitive sport

BPC-157 is prohibited for tested athletes. The US Anti-Doping Agency lists it as prohibited under the World Anti-Doping Agency's Prohibited List, in the category of S0, "Non-Approved Substances" — the class that catches any substance without government approval for human therapeutic use, rather than one that names every banned compound individually. USADA's own summary of the evidence echoes the clinical picture above: it states there are no human clinical trials establishing BPC-157's efficacy, and that human studies registered for it "appear to have been cancelled or stopped without any published conclusions."

What is known versus unknown

Known: BPC-157 is a well-defined, synthesizable 15-amino-acid sequence with a large and fairly consistent animal research literature behind it, concentrated heavily in one research group's output. Known: it has not been approved as a drug by the FDA or, as far as the published record shows, by any comparable regulator, and it is barred in Olympic and other tested sport.

Unknown: what the compound does in a human body under controlled conditions. No completed, published, controlled human trial exists to answer that question one way or the other. The single Phase I safety trial that could have started answering it was registered, run, and then had its results withdrawn before anyone outside the trial could see them — which leaves researchers exactly where they started, with an animal literature that can generate hypotheses but can't confirm or rule out what happens in people. That also means basic pharmacokinetic questions that matter for interpreting any future human study — how the peptide is absorbed, how long it persists, how it's cleared — remain answered only in rodent and canine data, not human data, which is a narrower and more specific gap than simply saying "it hasn't been studied enough."

What this means for researchers

The volume of BPC-157's animal literature can create an impression of certainty that the human evidence doesn't support. More than 150 published rodent and canine studies is a real research program, not nothing — but it answers a different question than "what does this do in humans," and the step from one to the other has, for this compound, barely been attempted in a way that produced a public result.

That distinction is also why a compound can simultaneously have an active, decades-long research literature and an entirely open regulatory and safety profile. Readers who want background on how BPC-157 sits alongside other peptides in a multi-compound research context can see the compound guide for KLOW, which covers BPC-157 as one of its four listed ingredients. The Journal has also covered the human side of this gap in more depth, including reported adverse events and the ongoing US compounding-policy debate, in a recent look at how BPC-157 use has outpaced its safety data.